Sustained exposure to the investigational kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: Results from two phase 1 studies

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  MacLean, David B ^a   Matsui, Hisanori ^a   Suri, Ajit ^a   Neuwirth, Rachel ^a   Colombel, Marc ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; HEALTH; HUMANS; KISSPEPTINS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; ORCHIECTOMY; PLACEBOS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84905833732     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4236     Document Type: Article

References (32)

1. CenterMM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61:1079-1092.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149.
4. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 2. Fort Washington, PA: National Comprehensive Cancer Network; 2013.
5. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet. 2010;376:1147-1154.
6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364:1995-2005.
7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:1187-1197.
8. Li N, Wang HX, Zhang J, Ye YP, He GY. KISS-1 inhibits the proliferation and invasion of gastric carcinoma cells. World J Gastroenterol. 2012;18:1827-1833.
9. Wang H, Jones J, Turner T, et al. Clinical and biological significance of KISS1 expression in prostate cancer. Am J Pathol. 2012;180: 1170-1178.
10. Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996; 88:1731-1737.
11. Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 1997;57:2384-2387.
12. Lee JH, Welch DR. Identification of highly expressed genes in metastasis- suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display. Int J Cancer. 1997;71:1035-1044.
13. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001; 276:34631-34636.
14. Murphy KG. Kisspeptins: regulators of metastasis and the hypothalamic- pituitary-gonadal axis. J Neuroendocrinol. 2005;17:519-525.
15. Nash KT, Phadke PA, Navenot JM, et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst. 2007;99:309-321.
16. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis inhumanmales. J Clin Endocrinol Metab. 2005;90:6609-6615.
17. Gottsch ML, Cunningham MJ, Smith JT, et al.Arole for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145:4073-4077.
18. Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun. 2004;320:383-388.
19. Messager S, Chatzidaki EE, Ma D, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release viaGprotein-coupled receptor 54. Proc Natl Acad Sci USA. 2005;102:1761-1766.
20. Navarro VM, Castellano JM, Fernandez-Fernandez R, et al. Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology. 2004;145:4565-4574.
21. Shahab M, Mastronardi C, Seminara SB, Crowley WF, Ojeda SR, Plant TM. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci USA. 2005;102:2129-2134.
22. Matsui H, Tanaka A, Yokoyama K, et al. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agentTAK- 448suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats. Endocrinology. 2012;153:5297-5308.
23. Asami T, Nishizawa N, Ishibashi Y, et al. Serum stability of selected decapeptide agonists of KISS1R using pseudopeptides. Bioorg Med Chem Lett. 2012;22:6391-6396.
24. Asami T, Nishizawa N, Ishibashi Y, et al. Trypsin resistance of a decapeptide KISS1R agonist containing an Nomega-methylarginine substitution. Bioorg Med Chem Lett. 2012;22:6328-6332.
25. Tanaka A, Matsui H, Asami T, et al. Suppression of testosterone release by chronic administration of investigational novel metastin analogs in male dogs and monkeys, and in healthy male volunteers. Paper presented at: 22nd European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics; Berlin, Germany: November 16-19, 2010.
26. Matsui H, Masaki T, Akinaga Y, et al. Anti-tumor growth effect of TAK-683, a metastin analogue, in preclinical androgen-dependent prostate cancer models. Paper presented at: 22nd European Organisation for Research and Treatment of Cancer-National Cancer Institute- American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics; Berlin, Germany: November 16-19, 2010.
27. Uenoyama Y, Inoue N, Pheng V, et al. Ultrastructural evidence of kisspeptin-gonadotrophin-releasing hormone (GnRH) interaction in the median eminence of female rats: implication of axo-axonal regulation ofGnRHrelease. J Neuroendocrinol. 2011;23:863-870.
28. Chan YM, Butler JP, Sidhoum VF, Pinnell NE, Seminara SB. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. J Clin Endocrinol Metab. 2012;97:E1458-E1467.
29. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator ofLHand increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96:E1228-E1236.
30. Jayasena CN, Nijher GM, Abbara A, et al. Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones inwomenwith hypothalamic amenorrhea. Clin Pharmacol Ther. 2010;88:840-847.
31. Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007;92:3958-3966.
32. Zajac M, Law J, Cvetkovic DD, et al. GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness. PLoS One. 2011;6:e21599.